Travere Therapeutics (TVTX) Gains from Investment Securities (2013 - 2026)

Travere Therapeutics has reported Gains from Investment Securities for 14 years, with the latest figure at $4000.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities fell 95.18% year-over-year to $4000.0; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (up 1020.33% YoY), and the FY2025 full-year result was $1.5 million, up 3542.5% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $4000.0, up from -$43000.0 in the prior quarter.
• The five-year high for Gains from Investment Securities was $9.1 million in Q1 2022, with the low at -$2.2 million in Q4 2023.
• Historically, Gains from Investment Securities has averaged $2.1 million across 5 years, with a median of $1.3 million in 2023.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities jumped 597.53% — and 2025, when it slumped 207.5%.
• Travere Therapeutics' Gains from Investment Securities stood at $6.4 million in 2022, then slumped by 134.35% to -$2.2 million in 2023, then surged by 101.83% to $40000.0 in 2024, then tumbled by 207.5% to -$43000.0 in 2025, then surged by 109.3% to $4000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $4000.0 (Q1 2026), -$43000.0 (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.